We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ABPI Respond To UK PM's Brexit Speech

ABPI Respond To UK PM's Brexit Speech content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), have responded to the Prime Minister's speech on the Government's negotiating objectives for exiting the EU.

​​​​Theresa May's speech was delivered today (Tuesday 17 January) at Lancaster House, and ​set out the 12 negotiating priorities for Brexit as part of the Plan for Britain after leaving the EU.

​“Today’s announcement is a welcome statement of intent that provides the UK’s pharmaceutical industry with confidence for the future."

The ABPI is pleased that the Prime Minister has identified Britain becoming the best place for science and innovation as one of her twelve negotiation priorities. Our continued leadership in this area will be crucial in creating a truly ‘global Britain’.

The Prime Minister has also said today that the UK’s new relationship with the EU will be set out by the end of the two-year period following the triggering of Article 50. Throughout this period, we will seek to secure the UK’s continued cooperation and alignment with EU rules for the regulation of medicines. This will be the best possible outcome for UK patients.

​We look forward to continuing to work with Government to make a success of the UK leaving the EU, securing a deal that builds upon our status as a global pharmaceutical industry leader."

Mike Thompson, ABPI, Chief Executive